Previous 10 | Next 10 |
Citi detailed why the selloff of Reata Pharmaceuticals (NASDAQ:RETA -17.0%) was overdone after the clinical-stage biopharma company fell on Monday in reaction to negative views cited by the FDA on amyotrophic lateral sclerosis therapy, AMX0035. Developed by Amylyx Pharmaceuticals (A...
Gainers: DatChat (DATS) +82%. Hycroft Mining Holding Corporation (HYMC) +66%. Plantronics (POLY) +50%. Kaixin Auto (KXIN) +31%. AMC Entertainment Holdings (AMC) +25%. TC Biopharm (TCBP) +23%. Creative Medical Technology (CELZ) +21%. Immunome (IMNM) +21%. Chi...
Stanley Druckenmiller’s 13F portfolio value decreased from $3.08B to $2.76B this quarter. Duquesne increased Coupang, Carvana, Kbr, Flex, Procept Bio, and Smartsheet while decreasing Alphabet, Amazon.com, Palo Alto Networks, Starbucks, and Expedia Group. They also dropped Meta ...
The clinical-stage biopharmaceutical company Reata Pharmaceuticals (RETA +0.9%) is trading higher in morning hours Thursday after Goldman Sachs imitated its coverage with a Buy recommendation citing the prospects of an experimental therapy for Friedreich’s ataxia (FA). Having started t...
New York, New York--(Newsfile Corp. - March 15, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) breached their fiduciary duties to shareholders. The investigation conc...
Reata Pharmaceuticals, Inc. (RETA) Q4 2021 Earnings Conference Call February 28, 2022, 08:30 AM ET Company Participants Warren Huff - Chief Executive Officer Colin Meyer - Chief Innovation Officer and Executive Vice President Manmeet Soni - Chief Operating Officer and Chief Financial Officer ...
Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...
Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...
Shares of Reata Pharmaceuticals (NASDAQ:RETA) are continuing to struggle in premarket trading after announcing Q4 2021 results that missed on the top line. Reata (RETA) had a tough end to last week when after Friday's market close, the company said it received a Complete Response Letter from ...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...